Neurodevelopmental outcomes of preterm infants fed high dose docosahexaenoic acid: A randomized controlled trial

M. Makrides, R.A. Gibson, A.J. Mcphee, C.T. Collins, P.G. Davis, L.W. Doyle, Karen Simmer, P.B. Colditz, S. Morris, L.G. Smithers, K. Wilson, P. Ryan

    Research output: Contribution to journalArticle

    254 Citations (Scopus)

    Abstract

    Context Uncertainty exists about the benefit of dietary docosahexaenoic acid (DHA) on the neurodevelopment of preterm infants.Objective To determine the effect of meeting the estimated DHA requirement of preterm infants on neurodevelopment at 18 months' corrected age.Design, Setting, and Participants Randomized, double-blind controlled trial enrolling infants born at less than 33 weeks' gestation from April 2001 to October 2005 at 5 Australian tertiary hospitals, with follow-up to 18 months.Intervention High-DHA (approximately 1% total fatty acids) enteral feeds compared with standard DHA (approximately 0.3% total fatty acids) from day 2 to 4 of life until term corrected age.Main Outcome Measures Bayley Mental Development Index (MDI) at 18 months' corrected age. A priori subgroup analyses were conducted based on randomization strata (sex and birth weight
    Original languageEnglish
    Pages (from-to)175-182
    JournalThe Journal of American Medical Association
    Volume301
    Issue number2
    DOIs
    Publication statusPublished - 2009

    Fingerprint Dive into the research topics of 'Neurodevelopmental outcomes of preterm infants fed high dose docosahexaenoic acid: A randomized controlled trial'. Together they form a unique fingerprint.

  • Cite this

    Makrides, M., Gibson, R. A., Mcphee, A. J., Collins, C. T., Davis, P. G., Doyle, L. W., Simmer, K., Colditz, P. B., Morris, S., Smithers, L. G., Wilson, K., & Ryan, P. (2009). Neurodevelopmental outcomes of preterm infants fed high dose docosahexaenoic acid: A randomized controlled trial. The Journal of American Medical Association, 301(2), 175-182. https://doi.org/10.1001/jama.2008.945